GlassScriptPhysician profile
Denka Marah
NPI 1669916961
$12,517.71
in general payments reported to CMS, 2019-2025
20 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,475 · 2022: $2,131 · 2023: $3,372 · 2024: $2,685 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,890 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,890.05 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,333.72 | 2021-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $3,454.96 | 2021-2025 | Biktarvy, Epclusa |
| Abbvie INC. | $1,484.79 | 2021-2025 | |
| Janssen Biotech, INC. | $575.19 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $565.65 | 2022-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Otsuka America Pharmaceutical, INC. | $498.05 | 2022-2025 | Rexulti |
| Napo Pharmaceuticals INC | $455.18 | 2021-2025 | Mytesi |
| Merck Sharp & Dohme LLC | $370.95 | 2021-2025 | Pifeltro, Delstrigo |
| Hikma Pharmaceuticals USA | $168.68 | 2022-2024 | Kloxxado, Ryaltris |
| Teva Pharmaceuticals USA, INC. | $103.59 | 2024-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $93.40 | 2023-2024 | Trelegy Ellipta |
| Alkermes, INC. | $83.20 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Janssen Products, LP | $73.57 | 2023 | Symtuza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.58 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $48.54 | 2024 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $41.45 | 2021 | |
| Qiagen, LLC | $37.80 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.30 | 2022 | |
| Hologic Sales and Service, LLC | $16.63 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denka Marah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.